Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent years emphasis has been given to investigate the role of vitamin D in areas beyond bone metabolism and maintenance of calcium homeostasis. Thus, vitamin D deficiency has been associated with risk factors for the occurrence of cardiovascular disease as well as with overall mortality.In addition, there are indications that a large proportion of the population (up to 50%) is vitamin D deficient. The measurement of vitamin 25 (OH) D3 levels is the best way to estimate the vitamin D actual reserves. It is worth mentioning that elevated levels of parathyroid hormone (PTH) \[5\] and reduced levels of 1,25 (OH)2 vitamin D3 (calcitriol have also been associated with cardiovascular disease.

The metabolic syndrome is a sum of risk factors for cardiovascular disease and is found in approximately 25% of the Greek population.There are a lot of data linking low vitamin D levels with the metabolic syndrome as a whole as well as with its individual characteristics. Specifically, vitamin D deficiency has been associated with increased incidence of hypertension, dyslipidemia, obesity, inflammation and dysglycemia.

Many studies have explored the effect of giving vitamin D supplements on the risk factors associated with the metabolic syndrome and the cardiovascular disease. The results of these studies are conflicting and this may partially be due to different doses of vitamin D used. The form of vitamin D most commonly used in these studies is cholecalciferol (vitamin D3.

Aim of the study:

Determination of the effect of cholecalciferol (VitD3) (2200 IU/day) on metabolic parameters in patients with metabolic syndrome.

Endpoints:

The primary endpoint will be changes in metabolic syndrome parameters 3 months after starting treatment:

* Waist circumference
* Blood pressure
* Levels of fasting serum triglycerides
* Levels of high-density lipoprotein cholesterol (HDL-C)
* Levels of fasting serum glucose.

The secondary endpoints will include changes in:

* The levels of low-density lipoprotein cholesterol (LDL-C) and non-HDL-C
* Subfractions of LDL-C \[average particle size of LDL-C, levels of small dense (sd) LDL-C\]
* Subfractions of HDL-C (levels of small and large particle HDL-C)
* The activity and levels of Lp-PLA2 (lipoprotein-associated phospholipase A2)
* The levels of serum apolipoprotein AI, A-II, AV, B, E, C-II, C-III and lipoprotein (Lp) (a)
* The activity of paraoxonase-1 (PON1)
* The concentration of pre-beta1-HDL
* The levels of hs-CRP (high sensitivity C-reactive protein)
* Oxidative stress as measured by levels of 8-isoprostane in the blood and urine and oxidized LDL (oxLDL)
* Adipokine levels (leptin, adiponectin, visfatin)
* Glucose homeostasis (index HOMA: fasting insulin X fasting glucose/405)
* The levels of glycosylated hemoglobin (HbA1c)
* The levels of 25 (OH) vitamin D3, of 1,25 (OH)2 vitamin D3 and PTH
* The levels of serum electrolytes (Ca, PO4) and the activity of alkaline phosphatase (ALP) in serum.

Study population:

The investigators will study patients with metabolic syndrome (n = 50 adults) attending the Outpatient Lipid and Obesity clinic at the University Hospital of Ioannina. Diagnosis of the Metabolic Syndrome will be based on the criteria of National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III).

All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes

NCT01479933

Prediabetic State Overweight Obese

COMPLETED NA

Effects of Vitamin D Supplementation in Obesity

NCT01037140

Vitamin D Deficiency Obesity

COMPLETED PHASE4

Vitamin D and Vascular Health in Children

NCT01797302

Obesity Vitamin D Deficiency

COMPLETED NA

Importance of Dosing Regimen for the Effect of Vitamin D Supplementation

NCT03272126

Hypovitaminosis D

COMPLETED PHASE3

Vitamin D Supplementation for the Prevention of Cardiovascular Risk

NCT02020694

Obesity Overweight Insulin Resistance

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D

All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.

Group Type ACTIVE_COMPARATOR

Vitamin D3

Intervention Type DRUG

2200 IU/day

Lifestyle measures

Group Type ACTIVE_COMPARATOR

Lifestyle advice

Intervention Type BEHAVIORAL

Diet and exercise

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D3

2200 IU/day

Intervention Type DRUG

Lifestyle advice

Diet and exercise

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

vitamin D Lifestyle measures

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with metabolic syndrome (n = 50 adults) attending the Outpatient Lipid and Obesity clinic at the University Hospital of Ioannina. Diagnosis of the Metabolic Syndrome will be based on the criteria of National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III).

Exclusion Criteria

* The study will exclude patients with triglyceride levels \>500 mg/dL,
* Diabetes mellitus, hypothyroidism (TSH \>5 IU/mL),
* Primary hyperparathyroidism, hypercalcemia of any cause,
* A history of taking formulations of calcium or vitamin D,
* Alcohol consumption \>3 drinks per day for men and \>2 drinks per day for women and women of childbearing age not taking contraceptive measures.
* Patients with hypertension may be included in the study if their blood pressure is \<140/90 and the antihypertensive treatment remains constant over the past 3 months (no change of antihypertensive medication during the study).
* Finally, patients receiving lipid-lowering medicines or patients who have stopped taking them for less than 4 weeks will be excluded from the study.

Minimum Eligible Age

16 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No